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Abstract
 
The activating receptor, NKG2D, is expressed on a variety of immune effector cells and recog-
nizes divergent families of major histocompatibility complex (MHC) class I–related ligands, in-
cluding the MIC and ULBP proteins. Infection, stress, or transformation can induce NKG2D
ligand expression, resulting in effector cell activation and killing of the ligand-expressing target
cell. The human cytomegalovirus (HCMV) membrane glycoprotein, UL16, binds to three of
the five known ligands for human NKG2D. UL16 is retained in the endoplasmic reticulum
and cis-Golgi apparatus of cells and causes MICB to be similarly retained and stabilized within
cells. Coexpression of UL16 markedly reduces cell surface levels of MICB, ULBP1, and
ULBP2, and decreases susceptibility to natural killer cell–mediated cytotoxicity. Domain
swapping experiments demonstrate that the transmembrane and cytoplasmic domains of UL16
are important for intracellular retention of UL16, whereas the ectodomain of UL16 participates
in down-regulation of NKG2D ligands. The intracellular sequestration of NKG2D ligands by
UL16 represents a novel HCMV immune evasion mechanism to add to the well-documented
viral strategies directed against antigen presentation by classical MHC molecules.
Key words: ULBP • MIC • NKG2D • UL16 • HCMV 
 
Introduction
 
Human cytomegalovirus is well adapted, establishing a life-
long, usually benign, relationship with most hosts. Typi-
cally, primary infections occur in childhood resulting in
mild or inapparent disease followed by asymptomatic, life-
time persistence of the virus with intermittent low level
shedding of infectious particles. However, in very young
children and immunocompromised individuals, human
CMV (HCMV)
 
* 
 
replicates to relatively high levels in sev-
eral different organs, frequently resulting in morbidity and
mortality (1). After reactivation from latency, HCMV faces
robust, fully primed host immunity. To counter this, the
virus uses a repertoire of immune evasion strategies that can
open “a window of opportunity” allowing virus replication
for a time or in a specific cell type. There are four mem-
brane glycoproteins encoded in the US region of the
HCMV genome (US2, US3, US6, and US11) that can in-
hibit the MHC class I antigen presentation pathway by in-
dependent mechanisms. These include prevention of cell
surface expression of MHC class I by retention in the ER,
increased degradation of MHC class I, and prevention of
the transport of peptides into the ER by the TAP trans-
porter (2, 3). In addition, two of these, US2 and US3, can
block MHC class II–mediated presentation to CD4
 
  
 
T
cells (4–6).
Decreased antigen presentation by virus-infected cells
would be expected to protect from T cell–mediated recog-
nition, but low levels of MHC class I expression might also
predispose these cells to lysis by NK cells, due to decreased
engagement of NK cell MHC class I–specific inhibitory
receptors. The importance of NK cells in controlling in-
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 Ad, adenovirus; endoH, endoglycosidase
H; GFP, green fluorescent protein; HCMV, human CMV; IRES, internal
ribosome entry site; LZ, leucine zipper; MCMV, mouse CMV; MFI,
mean fluorescence intensity; VSVG, vesicular stomatitis virus G protein.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
1428
 
NKG2D Ligand Intracellular Retention by HCMV UL16
 
fection by both HCMV and mouse CMV (MCMV) has
been documented (7, 8), but much less is known about
HCMV immune evasion mechanisms directed at NK cells.
Although HCMV-encoded proteins UL18 and UL40 have
been proposed to inhibit NK function by different mecha-
nisms, our understanding of how HCMV avoids immuno-
surveillance by NK cells is clearly incomplete (9–11).
Recent studies have revealed that NK cells and other
leukocytes express a variety of inhibitory and activating
receptors for classical and nonclassical MHC class I anti-
gens and other ligands. The balance between engage-
ment of these opposing classes of receptors is believed
to control leukocyte activation (12–14). One of the
activating receptors, the C-type lectin-like molecule,
NKG2D, has attracted particular attention as an impor-
tant mediator of innate and adaptive immune responses
(15). NKG2D is expressed on NK cells, CD8
 
  
 
T cells,
some 
 
   
 
T cells, some NK-T cells, and activated macro-
phages (16–22). NKG2D associates with the membrane-
bound signaling adaptor protein, DAP10, to transduce a
potent activating signal that can stimulate cytotoxicity,
proliferation, and the production of cytokines, chemo-
kines, and nitric oxide (16–19, 23–27). Very recently,
NKG2D was also shown to associate with the DAP12/
KARAP signaling adaptor in mouse NK cells and mac-
rophages (28, 29).
Ligands for NKG2D belong to distinct and divergent
families of nonclassical MHC class I–like molecules. Hu-
man MICA and MICB are encoded by closely related,
polymorphic genes that map to the MHC (30, 31). Like
classical MHC class I antigens, they contain 
 
 
 
1, 
 
 
 
2, and 
 
 
 
3
extracellular domains and are type 1 transmembrane pro-
teins. Human ULBP1, ULBP2, and ULBP3 genes map
outside the MHC on chromosome 6q25, and the encoded
proteins contain only 
 
 
 
1 and 
 
 
 
2 domains, and are glyco-
sylphosphatidylinositol-linked to the cell surface (24).
There are no known mouse equivalents to the MIC genes,
but several mouse ligands for NKG2D have been described
(18, 19, 32). All contain 
 
 
 
1 and 
 
 
 
2 domains, like ULBPs,
but with low sequence identity. The Rae1 proteins are
glycosylphosphatidylinositol-linked, whereas H60 and
MULT-1 are type 1 membrane proteins.
Studies on the regulation of NKG2D ligand expression
have shown increased MIC expression after heat shock, ox-
idative stress, transformation, and infection by certain vi-
ruses and bacteria (27, 33–38). NKG2D ligand expression
is commonly found on tumor-derived cell lines (18, 19, 24,
39, 40), and both H60 and Rae1 are induced in mouse skin
by carcinogen treatment (41). Studies using target cells
transfected with NKG2D ligands have shown that their ex-
pression stimulates NK cytotoxicity even in the presence of
normal levels of classical MHC class I antigens on the target
cells (16, 24). These findings support a general model in
which increased NKG2D ligand expression provides a
“danger” or “damage” signal to immune effector cells that
allows them to kill stressed, transformed, or infected cells
(15). Thus, the NKG2D/NKG2D ligand system poten-
tially represents a new type of immune surveillance mecha-
 
nism that can operate against cells with normal MHC class
I expression.
ULBP1 was initially discovered as a protein that bound
to the HCMV-encoded membrane glycoprotein, UL16.
This viral protein also binds to ULBP2 and MICB, but not
to ULBP3 nor MICA, suggesting that it might be involved
in subversion of the NKG2D system. Two possible mecha-
nisms by which this could occur in the context of a CMV-
infected cell were proposed. First, cell surface UL16 could
bind to cell surface NKG2D ligands and thereby prevent
NKG2D–NKG2D ligand interaction, or second, UL16
and NKG2D ligands could interact intracellularly to alter
the trafficking of NKG2D ligands and prevent their expres-
sion on the cell surface (24, 42). Here, we present evidence
that favors the second hypothesis, provides insight into the
mechanisms involved, and supports a role for UL16 as an
HCMV-encoded immunoevasion protein.
 
Materials and Methods
 
Cell Lines and Purification of Cells.
 
Daudi cells, transduced to
express MHC class I antigens and ULBP1, have been described
(24). EL4 (American Type Culture Collection TIB-39) are a mu-
rine T lymphoma cell line. His16 cells, a derivative of U373 hu-
man glioma cells, have been described (4). U373-MICBNeo15
(MBN15) were derived by transfecting U373 cells with pDC409-
MicB7 and pSV2-Neo, and selection in media containing 100
 
 
 
g/ml G418 sulfate (GIBCO BRL).
For data shown in Fig. 1, short-term cultured primary human
NK cells were obtained as previously described (43, 44). For data
shown in Figs. 8 and 9, freshly isolated primary human NK cells
were obtained from peripheral blood by negative selection using
the Rosette Sep human NK cell enrichment cocktail kit (Stem-
Cell Technologies Inc.) according to the manufacturer’s specifi-
cations.
Murine NK cells were expanded from splenocytes of C57BL/6
SCID or RAG2
 
    
 
mice (The Jackson Laboratory) by growth
for 4 d in 200 ng/ml rhuIL-15 (Immunex). Cultures containing
 
 
 
90% NK cells, as analyzed on day 3, were used in cytotoxicity
assays.
 
Adenovirus (Ad) Constructs.
 
Replication-defective (E1
 
 
 
) Ad
vectors expressing HCMV UL16, and the cellular proteins
MICB, MICA, and ULBP2 were constructed and propagated as
previously described (45). For glycoprotein expression, His16 or
MBN15 cells were coinfected with Ad vectors AdtetUL16,
AdtetMICB, AdtetMICA, or AdtetULBP2, and a second vector,
Adtet-transactivator (Adtet-Trans; using 20% of the amount of
other Ad vectors), which expresses a transactivator protein that
activates the promoter without the need for tetracycline.
AdtetUS9 (45) was used as a control Ad vector.
 
Flow Cytometric Analysis.
 
The following monoclonal anti-
bodies were used for flow cytometric analysis: M90, anti-
hCD40L used as a mouse IgG1 isotype control; M230, mouse
IgG1 anti-UL16; M291 and M295, mouse IgG1 anti-ULBP1;
M311, mouse IgG1 anti-ULBP2; M550, mouse IgG1 anti-
ULBP3; M673 mouse IgG1 anti-MICA; M360, mouse IgG1
anti-MICB; M2, rat IgG2a anti–muIL-4R; and M149, rat IgG2a
anti–muIL-15 used as a rat IgG2a isotype control.
Specific binding was detected with either a PE-conjugated
F(ab
 
 
 
)2 fragment goat anti–mouse IgG (Jackson ImmunoRe-
search Laboratories), a PE-conjugated F(ab
 
 
 
)2 fragment goat anti–T
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rat IgG (Jackson ImmunoResearch Laboratories), or FITC-con-
jugated goat anti–mouse IgG. After staining, cells were analyzed
on a Becton Dickinson FACScan™ or FACSCalibur
 
®
 
.
 
Confocal Immunofluorescence Microscopy.
 
MBN15 or His16 cells
were seeded onto 22-mm diameter glass coverslips overnight and
infected with Ad vectors for 12 h before fixing in PBS 4% para-
formaldehyde. Cycloheximide chase experiments were per-
formed as described above, with an additional 4 h of treatment
with 100 
 
 
 
g/ml cycloheximide. After permeabilization for 15
min with PBS 0.2% Triton X-100 and blocking for 1 h with PBS
2% goat serum, 1% fish gelatin, and 0.02% Tween 20, the cells
were incubated with primary antibodies diluted in blocking
buffer for 1 h. Antibodies to calreticulin and GM130 were ob-
tained from Transduction Laboratories. Rabbit antiserum to a
COOH-terminal peptide of UL16 (RLRIRLPHRYQRL-
RTED) was generated by immunizing rabbits with peptides con-
jugated onto keyhole limpet hemocyanin according to standard
protocols. Cells were washed extensively with PBS containing
0.02% Tween 20 and incubated with goat anti–mouse IgG Alexa
488 and goat anti–rabbit IgG Alexa 594 secondary fluorescent an-
tibodies (Molecular Probes) for 1 h, washed, and mounted with
Prolong anti-fade agent (Molecular Probes). Cell staining was vi-
sualized on a Bio-Rad 1024 ES laser scanning confocal system at-
tached to a Nikon Eclipse TE300 fluorescence microscope.
 
Labeling and Immunoprecipitation of Glycoproteins.
 
MBN15 or
Ad-infected His16 cells were radiolabeled with 150–250 
 
 
 
Ci/ml
[
 
35
 
S]methionine-cysteine (PerkinElmer) 20 h after infection for
the times indicated in the legends to the figures. After washing,
the label was chased by culture in media containing 20-fold ex-
cess methionine-cysteine. Cell extracts were made using NP-40/
deoxycholate lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mg/ml BSA,
and a cocktail of protease inhibitors). For immunoprecipitation,
primary antibodies were rabbit anti–UL16 peptide serum, mouse
anti–MICB, M360, or mouse anti–MICA, 3H5 (provided by T.
Spies, Fred Hutchinson Cancer Institute, Seattle, WA), and im-
mune complexes were collected with either protein A or protein
G agarose beads (GIBCO BRL). Endoglycosidase H (endoH)
 
f
 
analyses were performed with enzyme preparations and protocols
supplied by New England Biolabs, Inc. The protein samples were
subjected to SDS-PAGE using 12% gels followed by autoradiog-
raphy or PhosphorImager analysis.
 
Retroviral Vectors and Transduction.
 
EL4 cells were transduced
with amphotropic retroviruses generated by insertion of cDNAs
encoding ULBP1, ULBP2, ULBP3, or MICB into the LZR-
SpBMN-Z vector (46) followed by transfection into the Phoenix
packaging line, or with vesicular stomatitis virus G protein
(VSVG)-pseudotyped retroviruses (47) generated using the
pBMN-internal ribosome entry site (IRES)-green fluorescent
protein (GFP) vector in the 293GP packaging line (vectors and
cells were provided by the Nolan Lab, Stanford University, Palo
Alto, CA).
 
Construction and Expression of UL16/IL-4R and IL-4R/UL16
Chimeric Protein Retroviral Constructs.
 
The UL16/IL-4R chimera
contains the extracellular domain of UL16 through residue 187,
with a HindIII site 5
 
  
 
and a BglII site 3
 
 
 
, fused to the transmem-
brane domain of the truncated murine IL-4R (IL-4R; reference
48) from residues 232 up to and including 258, with a BglII site 5
 
 
 
and a NotI site 3
 
 
 
. This was then subcloned into the LZRSpBMN-Z
vector, excised with SrfI, which cuts within the Psi sequence, and
NotI, and subcloned into the pBMN-IRES-GFP vector.
The IL-4R/UL16 chimera contains the extracellular domain
of the IL-4R through residue 231, with a HindIII site 5
 
  
 
and a
BglII site 3
 
 
 
, fused to the transmembrane and cytoplasmic do-
mains of UL16 from residues 188 up to and including 230, with a
BglII site 5
 
  
 
and a NotI site 3
 
 
 
. This was then subcloned into the
pBMN-IRES-GFP vector as described above. The sequences of
the oligonucleotide primers used to amplify the selected se-
quences by PCR are available upon request.
 
Immunoblotting.
 
Proteins (15 
 
 
 
g of total EL4 lysate or 2 
 
 
 
g of
CV-1 lysate) were treated with 2 
 
 
 
l recombinant 
 
N
 
-glycanase
(Glyko), separated on 1-mm thick 4–20% Tris glycine gels, and
transferred to nitrocellulose filters. UL16 was detected with mAb
M230 (1 
 
 
 
g/ml in PBS containing 2.5% BSA), followed by
horseradish peroxidase–conjugated goat anti–mouse IgG (1:4,000
in PBST). Immunoreactive bands were visualized by enhanced
chemiluminescence (Amersham Biosciences). Blots were stripped
and reprobed with 0.5 
 
 
 
g/ml rabbit anti–STAT5a (Upstate Bio-
technology) and horseradish peroxidase–conjugated goat anti–
rabbit IgG (1:2,500 in PBST).
 
Cytotoxicity Assay.
 
Cytotoxicity assays were performed in the
presence of Fab fragments of specific antibodies or leucine zipper
(LZ) fusion proteins. UL16LZ has been described (24). 5 
 
  
 
10
 
5
51
 
Cr-labeled targets were incubated with 50 
 
 
 
g of the Fab frag-
ments or LZ proteins for 20 min at 37
 
 
 
C, washed with media,
and plated at 10
 
4 
 
cells/well. Effectors were added and assays were
performed as previously described (24).
 
Results
 
UL16 Is Not an Effective Competitor of NKG2D–NKG2D
Ligand Interaction.
 
Previous experiments had shown that
soluble UL16 prevented binding of ULBP1 to cell surface–
expressed NKG2D, suggesting that UL16 could be a bio-
logical antagonist of NKG2D ligands (24). To test this
hypothesis, soluble recombinant UL16 was added to a cy-
totoxicity assay that measured the ability of human NK
cells to kill Daudi cells that coexpressed MHC class I and
ULBP1. Previous work had shown that cytotoxicity in this
system was dependent on ULBP1 expression and that kill-
ing could be blocked by anti-ULBP1 Fab (24) or anti-
NKG2D Fab (unpublished data). In contrast, no diminu-
tion of killing was seen with the addition of soluble UL16
(UL16LZ, Fig. 1). In other studies, we were unable to de-
tect binding of UL16 to ULBP1, ULBP2, or MICB pro-
teins using Biacore technology, under conditions where
binding of these ligands to NKG2D was readily measured
(unpublished data). The relatively weak binding of soluble
UL16 to NKG2D ligands, compared with the relatively
strong binding of NKG2D to NKG2D ligands, make it un-
likely that UL16 could be an effective direct competitor for
NKG2D–NKG2D ligand interactions.
 
UL16 Accumulates in the ER and cis-Golgi Apparatus.
 
The UL16 coding sequence predicts a type 1 membrane
glycoprotein that could act to bind NKG2D ligands either
in cytoplasmic membranes or on the cell surface. To exam-
ine the subcellular localization of UL16, we constructed a
replication-defective Ad vector, AdtetUL16, that expresses
UL16. His16 human glioma cells were infected with
AdtetUL16, radiolabeled in a pulse-chase format, and
UL16 was immunoprecipitated from cell extracts. Samples
were treated with endoH, which removes high mannose
oligosaccharides characteristic of glycoproteins in the ERT
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and cis-Golgi. After a short pulse labeling, UL16 was
largely or entirely sensitive to endoH, shifting to a faster
migrating form without 
 
N
 
-linked oligosaccharides (Fig. 2
A). Although glycoproteins that move out through the
Golgi apparatus and to the cell surface become endoH re-
sistant, UL16 remained predominantly endoH sensitive for
the entire 8-h chase period.
Confocal immunofluorescence microscopy indicated
that UL16 was found in perinuclear cytoplasmic mem-
branes and rarely on the surfaces of cells (Fig. 2 B). UL16
extensively colocalized with the ER proteins, calnexin
(Fig. 2 B), and calreticulin (unpublished data). There was
also colocalization with two markers found predominately
in the cis-Golgi apparatus, GM130 (Fig. 2 B) and p115
(unpublished data). The amount of UL16 that colocalized
with these two Golgi apparatus markers was always less
than with ER markers. We concluded that UL16 largely
accumulates in the ER and to a lesser extent in the cis-
Golgi apparatus, with little of the glycoprotein reaching the
cell surface.
 
UL16 Prevents Cell Surface Expression of NKG2D
Ligands.
 
To test the hypothesis that UL16 might function
to alter the intracellular trafficking or sorting of NKG2D
ligands, MICB and UL16, or MICB and a control protein
US9, were coexpressed in His16 cells using Ad vectors.
Cell surface expression of MICB was reduced by 
 
 
 
90%
when UL16 was coexpressed compared with cells infected
with the control Ad vector (Fig. 3, A and B). Two other
NKG2D ligands, ULBP2, which is known to bind UL16,
and MICA that does not bind UL16 (24), were also ex-
pressed using Ad vectors. UL16 reduced cell surface expres-
sion of ULBP2, but not MICA (Fig. 3 C). Therefore, there
is a correlation between UL16 binding of NKG2D ligands
and down-regulation of their cell surface expression.
 
UL16 Causes MICB, but Not MICA, to be Retained in the
ER and Golgi Apparatus and Stabilizes MICB.
 
To further
characterize the effects of UL16 on MICB, a stably trans-
fected cell line, MBN15, was produced that expresses
MICB. MICB was immunoprecipitated from radiolabeled
MBN15 cells in a pulse-chase format, and subsequently
treated or not treated with endoH. In uninfected cells or
cells infected with a control Ad vector, MICB was found
largely as a single 41-kD protein species that was entirely
endoH sensitive after the 10-min pulse labeling period.
However, after the 60-min chase period a large fraction of
the MICB displayed an increased apparent molecular
weight of 
 
 
 
44–52 kD, and these mature species were resis-
tant to endoH (Fig. 4 A, top). By contrast, in cells infected
with AdtetUL16, MICB remained largely in the faster mi-
Figure 1. Soluble UL16 does not block ULBP-mediated cytotoxicity.
Daudi cells expressing MHC class I and ULBP1 were used as targets in cy-
totoxicity assays using human NK cells, at the indicated effector/target ra-
tios. Class I /ULBP1  Daudi targets were preincubated with the anti-
ULBP1 Fab, M291, a control Fab, the UL16LZ protein, or a control LZ
protein (RANK ligand-LZ), before the addition of effector cells. Individual
data points are calculated from the averages of triplicate samples. The results
shown are representative of three experiments using three separate donors.
Figure 2. UL16 is a stable, highly glycosylated protein that localizes to
the ER/cis-Golgi regions. (A) His16 cells were infected with AdtetUL16
and Adtet-trans (50 and 10 PFU/ml, respectively) for 20 h. Infected cells
were labeled with [35S]methionine, a 10-min pulse (labeled P), and chases
for the indicated times (in minutes, labeled C). UL16 was immunoprecip-
itated from cell lysates with rabbit anti–UL16-C-terminal peptide sera.
For endoH treatment, samples were divided in half and not treated ( ) or
treated ( ) with endoH. Immunoprecipitates were analyzed by SDS-
PAGE and autoradiography. Bands representing UL16 or UL16 with
N-linked oligosaccharides removed (UL16-CHO) are indicated. Pre-
immune rabbit serum did not precipitate these bands (unpublished data).
(B) His16 cells were infected with AdtetUL16 and Adtet-trans (25 and 5
PFU/cell, respectively). After 12 h the cells were fixed, permeabilized,
and incubated simultaneously with rabbit anti–UL16-C (red) and mouse
antibodies to the cellular markers calnexin (green) and gm130 (green) as
indicated. Primary antibodies were visualized with secondary fluorescent
antibodies using a scanning laser confocal microscope. No staining was
seen with preimmune rabbit serum (unpublished data).T
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grating immature form that was endoH sensitive. To char-
acterize the effects of UL16 on MICA, His16 cells were
coinfected with AdtetMICA and AdtetUL16, or Adtet-
MICA and AdtetUS9. Similarly to MICB, MICA dis-
played an apparent molecular weight of 
 
 
 
41 kD after a
short pulse labeling period and this species was endoH sen-
sitive (Fig. 4 A, bottom). The electrophoretic mobility of
MICA decreased after the 60-min chase period and the
glycoprotein was endoH resistant. Processing of MICA was
not affected by UL16. We conclude that UL16 inhibits the
processing of MICB to mature, endoH-resistant forms of
the glycoprotein, but does not affect trafficking of MICA.
These results are consistent with the hypothesis that in cells
expressing UL16, most of the MICB leaves the ER slowly,
or not at all, and does not reach the trans-Golgi apparatus.
UL16 was found in perinuclear membranes, colocalizing
with ER and cis-Golgi markers. To characterize the sub-
cellular distribution of MICB in cells expressing UL16,
MBN15 cells were infected with AdtetUL16 or a control
Ad vector and stained with anti-MICB and anti-UL16 an-
tibodies. Confocal microscopy indicated that UL16 exten-
sively colocalized with MICB in a perinuclear region of the
cells (Fig. 5, A–C). In cells infected with the control Ad
vector, MICB was distributed more uniformly throughout
the cytoplasm and a large fraction of the protein was on the
cell surface (Fig. 5, D–F). Therefore, UL16 caused MICB
to be retained in perinuclear cytoplasmic membranes of
cells, consistent with the endoH analyses.
Based on pulse-chase and endoH digestion experiments,
MICB traffics quickly from the ER through the Golgi ap-
paratus to the cell surface and UL16 blocks this transport.
The confocal experiments in Fig. 5, A–F, measure steady
Figure 3. UL16 reduces cell surface expression of
NKG2D ligands. (A and B) His16 cells were infected
with 50 PFU/cell AdtetMICB and coinfected with
AdtetUL16 and Adtet-trans (30 and 6 PFU/cell, re-
spectively) to induce UL16 expression, or with
Adtet-trans alone as a negative control (36 PFU/cell)
for 20 h. Cells were stained with anti-MICB M360 and
analyzed by flow cytometry. In A: thin black line,
AdtetUL16-infected cells; thick gray line, Adtet-trans
infected cells; dotted line, secondary antibody control.
B quantitates cell surface expression of MICB on cells
infected with Adtet-trans versus AdtetUL16. (C) His16
cells were coinfected with AdtetMICA, AdtetMICB,
or AdtetULBP2 and Adtet-trans (50 and 10 PFU/cell,
respectively). The cells were also infected with
AdtetUL16 and Adtet-trans (50 and 10 PFU/cell, re-
spectively) or as negative control with AdtetUS9 and
Adtet-trans (also 50 and 10 PFU/cell, respectively) for
20 h. Cells were stained with anti-MICA M673, anti-
MICB M360, and anti-ULBP2 M311. The mean fluo-
rescence in each sample was normalized to the values
obtained when cells were transduced with each of the
NKG2D ligands alone. These results are representative
of three separate experiments.
 
Figure 4.
 
UL16 causes intracellular retention and stabilization of
MICB. (A) MICB-transfected MBN15 cells (top) or His16 cells express-
ing MICA after infection with AdtetMICA and Adtet-trans (50 and 10
PFU/cell, respectively) were coinfected with AdtetUL16 (100 PFU/cell)
or AdtetUS9 (100 PFU/cell) and Adtet-trans (20 PFU/cell) for 20 h or
were left uninfected. Infected cells were labeled for 10 min with
[
 
35
 
S]methionine and the label was chased for 60 min. MICB and MICA
were immunoprecipitated from cell extracts with mouse monoclonal anti-
bodies M360 and 3H5, respectively, treated with endoH where indicated,
and analyzed by SDS-PAGE and phosphorimager. The positions of mo-
lecular weight markers of 45 and 31 kD and of several species representing
mature MICB and MICA, as well as MICB and MICA with 
 
N
 
-linked oli-
gosaccharides removed (MICB-CHO, MICA-CHO), are indicated. MICA-
and MICB-specific bands were identified by comparison with immunopre-
cipitates using isotype control antibodies and untransfected or uninfected
cells (unpublished data). (B) MBN15 cells infected with AdtetUS9 or
AdtetUL16 as described above were labeled for 10 min with [
 
35
 
S]methio-
nine (labeled P) and the label was chased for the indicated times (in min,
labeled C). MICB was immunoprecipitated as described above.T
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state levels of MICB. To trace the fate of MICB molecules
produced after expression of UL16, MBN15 cells infected
with AdtetUL16 or a control Ad vector were treated with
cycloheximide to block protein synthesis. After 4 h of cy-
cloheximide treatment, confocal microscopy of UL16-
expressing cells revealed MICB in a perinuclear location
colocalized with UL16 (Fig. 5, G–I). In contrast, MICB
was largely undetectable after 4 h of cycloheximide treat-
ment in cells infected with a control Ad vector (Fig. 5,
J–L). To examine turnover of MICB directly, MBN15
cells were infected with AdtetUL16 or a control Ad vector,
radiolabeled, and MICB was immunoprecipitated after
longer chase periods. After 4 h, there was a marked loss of
MICB in cells infected with the control Ad vector. Phos-
phorImager analysis of the 4-h chase compared with pulse
samples indicated that 
 
 
 
90% of the MICB protein was lost.
By contrast, MICB was more stable in cells coexpressing
UL16 (Fig. 4 B), with only an 11% loss of MICB during
the 4-h chase period. Much of the MICB observed after
the 4-h chase remained sensitive to endoH and was stabi-
lized by the presence of UL16. It appears that in the ab-
sence of UL16, MICB reaches the cell surface relatively
quickly, within 60–90 min, and is then rapidly turned over.
The presence of UL16 prevents transport of MICB to the
cell surface and reduces turnover.
 
Down-regulation of Cell Surface Expression of NKG2D
Ligands by UL16.
 
To examine in more detail the conse-
quences of coexpression of UL16 and NKG2D ligands on
susceptibility to NK cytotoxicity, we wished to use stable
transduction of a cell type that lacked expression of endog-
enous NKG2D ligands. His16 cells express several human
NKG2D ligands and were efficiently killed by NK cells
Figure 5. MICB colocalizes with
UL16 and is retained/stabilized by
the interaction. MBN15 cells ex-
pressing MICB were infected with
either AdtetUL16 (25 PFU/cell) in
A, B, C, G, H, and I or AdtetUS9
(25 PFU/cell) in D, E, F, J, K, and L
and Adtet-trans (5 PFU/cell; in all
cases) for 12 h. The infected cells
were fixed immediately (A–F) or in-
cubated for 4 h with 100  g/ml cy-
cloheximide and then fixed (G–L).
The cells were permeabilized and
incubated simultaneously with anti-
MICB M360 (green) and rabbit
anti–UL16-C sera (red), followed by
secondary fluorescent antibodies and
visualized by confocal microscopy.
No staining was seen with preimmune
rabbit serum or isotype control mono-
clonal antibody (unpublished data).T
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(unpublished data), but EL4 mouse thymoma cells have
been shown to lack detectable expression of NKG2D
ligands (18, 19, unpublished data) and were chosen for
these experiments. EL4 cells were separately transduced
with retroviral vectors expressing ULBP1, ULBP2,
ULBP3, and MICB. Cell populations expressing high lev-
els of the human NKG2D ligands were derived by cell
sorting using specific antibodies to the ligands. UL16 was
transduced into each of these EL4 cell populations using a
bicistronic retroviral vector in which the UL16 cDNA was
followed by an IRES and cDNA encoding GFP. GFP-
expressing cells were enriched by cell sorting and analyzed
by flow cytometry for NKG2D ligand and GFP expression.
Fig. 6 A shows that the NKG2D ligand-transduced cells
express uniformly high levels of MICB and the ULBPs, but
that transduction by the UL16-IRES-GFP retrovirus fol-
lowed by a single round of sorting for GFP-expressing cells
resulted in decreased levels of cell surface MICB, ULBP1,
and ULBP2 in a substantial fraction of cells. In contrast,
surface expression of ULBP3, which does not bind to
UL16 (24), was unchanged by the presence of UL16.
To determine if the down-regulation of cell surface
ULBP2 was directly correlated with UL16 expression,
the heterogeneous population of UL16-IRES-GFP–trans-
duced cells was further sorted by flow cytometry into those
expressing higher cell surface levels of ULBP2 (BP2
 
hi
 
/
UL16) and those that expressed lower or undetectable lev-
els (BP2
 
low
 
/UL16; Fig. 6 B). UL16 expression in these
populations was assessed by Western blot with a mono-
clonal antibody specific to UL16. Fig. 6 C shows that there
was an inverse correlation between UL16 expression and
cell surface ULBP2 expression. These findings confirm that
UL16 is able to cause down-regulation of cell surface ex-
pression for all the NKG2D ligands to which it can bind.
 
UL16 Transmembrane and Cytoplasmic Domains Contribute
to Intracellular Retention of UL16, Yet the Ectodomain Can Re-
duce Cell Surface Expression of ULBP2.
 
To examine which
sequences within UL16 were responsible for intracellular
retention, we constructed chimeric proteins between UL16
and a truncated mouse IL-4R that has a very short cyto-
plasmic domain and is readily expressed on the cell surface
(48). These chimeric proteins were expressed using retrovi-
ral vectors in which the UL16/IL-4R chimeric cDNA was
followed by an IRES and GFP. After transduction of EL4
cells or EL4 cells expressing ULBP2, transduced cells were
enriched by sorting for GFP expression. As shown in Fig.
7, A and C, full-length UL16 transduction gives no detect-
able cell surface expression of UL16 despite abundant intra-
cellular staining. When the extracellular domain of the IL-
4R was fused to the UL16 transmembrane and cytoplasmic
domains (IL-4R/UL16), there was no detectable surface
expression of the chimeric protein, but it was readily de-
tected intracellularly (Fig. 7, B and C). In contrast, replace-
ment of the UL16 transmembrane and cytoplasmic do-
mains by those of the IL-4R (UL16/IL-4R) allows cell
surface expression of the UL16 ectodomain in a consider-
Figure 6. UL16 decreases cell surface expression
of ULBP1, ULBP2, and MICB, but not ULBP3,
in EL4 cells. (A) EL4 cells expressing the ULBPs or
MICB were further transduced with retroviruses
encoding both UL16 and GFP. Transduced cells
were enriched by one round of fluorescence-acti-
vated cell sorting for cells expressing GFP, stained
with specific monoclonal antibodies, and analyzed
by flow cytometry. (B) EL4 cells transduced with
ULBP2 and UL16 (ULBP2 /UL16 EL4) were fur-
ther sorted by flow cytometry to obtain populations
expressing high (BP2hi/UL16 EL4) or low (BP2low/
UL16 EL4) cell surface levels of ULBP2. (C) Cell
lysates were prepared from ULBP2   EL4 cells,
ULBP2 /UL16 EL4 cells, ULBP2hi/UL16 EL4
cells, ULBP2low/UL16 EL4 cells, or from CV-1
cells transiently transfected with an expression vec-
tor alone (vector) or with an expression vector
containing the gene for UL16. Cell lysates were
treated with N-glycanase and analyzed by immuno-
blotting with anti-UL16 M230. Blots were stripped
and reprobed with anti-STAT5 to demonstrate
equal protein loading.T
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able fraction of transduced cells (Fig. 7 C). These results
demonstrate that the UL16 transmembrane and cytoplas-
mic domains of UL16 contribute to intracellular retention
of UL16 and can also dictate intracellular localization when
fused to ectodomains of proteins that are normally located
on the cell surface.
The retrovirus vectors encoding the chimeric constructs
were then transduced into EL4 cells expressing ULBP2 and
sorted for GFP expression (Fig. 7 D). Surprisingly, UL16/
IL-4R substantially reduced cell surface expression of
ULBP2 to an extent that was comparable to full-length
UL16. The IL-4R/UL16 construct had no effect on
ULBP2 surface expression (Fig. 7 D). Thus, the UL16
ectodomain, in the absence of UL16 transmembrane and
cytoplasmic domains, was able to down-regulate NKG2D
ligand surface expression.
 
Functional Cross-Reaction of Human NKG2D Ligands with
Mouse NKG2D.
 
Previous work had shown that human
NK cells could recognize ULBP and MIC when they
were expressed in human target cells (24). To determine
whether human or mouse NK cells would be able to me-
diate efficient NKG2D-mediated cytotoxicity against hu-
man NKG2D ligands expressed in mouse target cells, we
used the EL4 lines expressing human NKG2D ligands
as targets in cytotoxicity assays. MICB, ULBP1, and
ULBP2-expressing EL4 cells were killed efficiently by IL-
15–activated mouse NK cells compared with the parental
EL4 cells, whereas ULBP3-expressing EL4 cells were
Figure 7. The UL16 transmembrane and cyto-
plasmic domains are involved in the intracellular
retention of UL16, whereas the UL16 ectodomain
is required for intracellular retention of ULBP2. (A)
EL4 cells or EL4 cells transduced with a VSVG-
pseudotyped retrovirus encoding UL16 and GFP
were incubated in the presence or absence of 0.1%
saponin to permeabilize cells. Cells were stained
with anti-UL16 M230 or an isotype control anti-
body, fixed with 2% paraformaldehyde, and ana-
lyzed via flow cytometry. The histograms depict
the mean fluorescence intensity (MFI) of cells
stained with M230 minus the MFI of the cells
stained with the control antibody. The results
shown are representative of three separate experi-
ments. (B) EL4 cells or EL4 cells transduced with a
VSVG-pseudotyped retrovirus encoding the IL-4R/
UL16 chimeric protein and GFP were stained as
described above with anti-murine IL-4R M2 or an
isotype control antibody. The histograms shown
depict the MFI of cells stained with M2 minus the
MFI of the cells stained with the isotype-matched
control antibody. The results shown are representa-
tive of three separate experiments. (C) ULBP2 
EL4 cells were transduced with VSVG-pseudo-
typed retroviruses encoding UL16 and GFP, the
UL16/IL-4R chimera and GFP, and the IL-4R/
UL16 chimera and GFP. Transduced cells were en-
riched by fluorescence-activated cell sorting for
cells expressing GFP, stained with anti-UL16 or
with anti–IL-4R M2, and analyzed by flow cytom-
etry. (D) ULBP2  EL4 cells were transduced with
VSVG-pseudotyped retroviruses encoding UL16
and GFP, the UL16/IL-4R chimera and GFP, and
the IL-4R/UL16 chimera and GFP. Transduced
cells were enriched by fluorescence-activated cell
sorting of cells expressing GFP, stained with anti-
ULBP2 M311, and analyzed by flow cytometry.T
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killed at the same level as the parental EL4 cells (Fig. 8 A).
The cytotoxicity results correlated completely with bind-
ing experiments showing that ULBP1, ULBP2, and
MICB, but not ULBP3, could bind to recombinantly ex-
pressed mouse NKG2D (unpublished data). The enhanced
killing was completely blocked by a monoclonal antibody
directed against mouse NKG2D, demonstrating specificity
(unpublished data). When human NK cells were tested
against the same panel of mouse targets, all the transduc-
tants were killed more efficiently than EL4 cells and killing
was blocked by a monoclonal antibody directed against
human NKG2D (Fig. 8 B and unpublished data). These
experiments establish that both mouse and human NK
cells can recognize the human NKG2D ligands expressed
in mouse lymphocytes.
 
UL16 Expression Increases Resistance to NKG2D Ligand–
mediated NK Cytotoxicity.
 
The preceding experiments es-
tablished that UL16 was able to interact intracellularly with
NKG2D ligands, altering their trafficking within the cell
and decreasing their cell surface expression. To determine
how this might affect recognition of the cells by NKG2D-
expressing immune effector cells, EL4 cells expressing the
NKG2D ligands, ULBP1, ULBP2, and MICB, were trans-
duced with the UL16-IRES-GFP retroviral vector, sorted
into populations expressing GFP (designated UL16
 
 
 
), or
not expressing GFP (designated UL16
 
 
 
), and examined for
their ability to act as targets for NK cytotoxicity. As shown
in Fig. 9, cells expressing these NKG2D ligands were effi-
ciently killed by mouse NK cells (Fig. 9, A and B, ULBP1
and ULBP2) or human NK cells (Fig. 9 D, MICB) com-
pared with EL4 cells. NKG2D ligand–expressing cells
transduced with UL16-IRES-GFP and sorted for GFP ex-
pression were killed much less efficiently than the GFP
 
 
 
cells. Expression of UL16 in EL4 cells or EL4 cells express-
ing ULBP3 did not change their sensitivity to killing by
mouse or human NK cells (Fig. 9 C and unpublished data).
The correlation between increased UL16 expression, de-
creased cell surface NKG2D ligand expression, and de-
creased killing by NK cells, together with the intracellular
colocalization of UL16 and the NKG2D ligands, establishes
a mechanism by which UL16 would be able to protect
HCMV-infected cells from immune surveillance by pre-
venting the cell surface expression of the NKG2D ligands.
 
Discussion
 
The central findings described here are that UL16 causes
the NKG2D ligands, ULBP1, ULBP2, and MICB, to be
retained in the ER and cis-Golgi apparatus of cells so that
these molecules do not reach the cell surface, resulting in
increased resistance to NK cell cytotoxicity. These data are
consistent with a role of UL16 as a viral immunomodula-
tory protein that enables HCMV-infected cells to avoid
recognition by immune effector cells that express NKG2D.
Although our data examine only NK cells, it is likely that
decreased cell surface expression of NKG2D ligands would
increase resistance to killing of HCMV-infected cells by
CD8
 
  
 
or     T cells, given the demonstrated role of
NKG2D ligands in stimulating cytotoxicity by these effec-
tor cells (27, 35).
The predicted protein sequence of UL16 suggests a type
1 membrane glycoprotein. When expressed in cells, the
majority of UL16 was found in perinuclear membranes that
also stained with antibodies specific to ER and cis-Golgi
proteins. Little or no UL16 was found on the cell surface,
either by cell surface staining or confocal microscopy.
UL16 oligosaccharides were not processed from high man-
nose to complex oligosaccharides, a process that is com-
pleted in the trans-Golgi, supporting the hypothesis that
UL16 does not traffic extensively beyond the cis- or me-
dial-Golgi compartments and is largely retained in the ER.
Alternatively, there might be transport from the ER and
retrieval from the ER Golgi intermediate compartment or
cis-Golgi apparatus back to the ER.
Efficient intracellular retention of UL16 required its own
transmembrane and cytoplasmic domains. In their absence
some of the UL16 reached the cell surface. These domains
can function to retain the extracellular domain of the mIL-
4R within the cell, indicating that they contribute substan-
tially to ER localization. The amino acids within these
domains that mediate retention are not yet defined. Inspec-
tion of the UL16 cytoplasmic amino acid sequence does
not reveal known endoplasmic reticulum retention motifs
such as di-lysine residues, or KDEL motifs. Arginine-rich
sequences have been shown to function as endoplasmic
reticulum retention motifs (49) and the short cytoplasmic
domain of UL16 is rich in clustered arginine residues. No-
tably, most arginines are followed by a hydrophobic amino
Figure 8. Enhanced cytotoxicity of human and mouse NK cells against
EL4 cells transduced with ULBPs or MICB. (A) EL4 cells expressing
ULBP1, ULBP2, ULBP3, or MICB were tested as targets in cytotoxicity
assays using mouse NK cells as effectors. Individual data points are calcu-
lated from the averages of triplicate samples. The results shown are repre-
sentative of three separate experiments. (B) EL4 cells expressing ULBP2,
ULBP3, or MICB were tested as targets in cytotoxicity assays using hu-
man NK cells as effectors. The results shown are from a single donor and
are representative of three experiments using three separate donors.T
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acid (RIPQRLCQRLRIRLPHRYQ  RLRTED). Addi-
tionally, a YQRL sequence is present that matches a con-
sensus tyrosine-based sorting signal, Yxx , where   is a
hydrophobic amino acid. Such tyrosine-based signals are
used for protein sorting between many different subcellular
compartments, depending on the context of the sequence
and which adaptor protein complexes are bound (50). Mu-
tational analysis will be required to determine which resi-
dues contribute to the intracellular trafficking of UL16.
UL16 expression in cells caused MICB and other
NKG2D ligands to accumulate in cytoplasmic membranes.
In the case of MICB, this accumulation was largely or ex-
clusively in perinuclear membranes. Consistent with the
notion that MICB accumulated in the ER/cis-Golgi, we
found extensive colocalization of UL16 with MICB. UL16
expression also dramatically stabilized MICB within the
cell. Confocal microscopy of cells expressing UL16, and
treated with cycloheximide for 4 h, detected MICB in a
perinuclear location. However, in the absence of UL16,
MICB was not detected after 4 h of protein synthesis inhi-
bition. Pulse-chase analysis also confirmed the rapid turn-
over of MICB and its stabilization by UL16. The precise
molecular mechanisms responsible for these changes are
not yet known, but it is possible to speculate as to how this
might occur. The intracellular half-life of UL16 is long, as
we observed little loss of the protein during an 8-h chase
period. It is possible that binding of UL16 to MICB forms
a relatively stable intracellular complex in the ER and cis-
Golgi apparatus. In the absence of UL16, MICB moves
rapidly to the Golgi apparatus and then to the cell surface,
largely acquiring endoH resistance within 60 min. Turn-
over from the cell surface is likely to involve endocytosis
and delivery to lysosomes for degradation, as well as enzy-
matic shedding, which has been described for MICA and
ULBP2 (37, 51, 52). Intracellular retention of MICB by
UL16 would preclude this turnover.
The cytoplasmic and transmembrane domains of UL16
clearly play a role in intracellular traffic and intracellular re-
tention. When these domains were replaced with those of
the IL-4R (IL-4R/UL16), there was detectable expression
of the UL16 ectodomain on the cell surface. However,
when the UL16 ectodomain was fused with the IL-4R
transmembrane and cytoplasmic domains (UL16/IL-4R),
the chimeric protein retained the ability to reduce cell sur-
face expression of NKG2D ligands. To explain these find-
ings, one hypothesis is that a proportion of the UL16/IL-4R
chimera is still retained in the cytoplasm, by mechanisms
involving the ectodomain of UL16, and is able to bind
NKG2D ligands and retain or missort these complexes
within cells. This model suggests that some of the sorting
signals reducing UL16 surface expression would be present
in the ectodomain. Alternatively, UL16 may function in a
similar fashion as has been proposed for the HCMV US3
and the murine CMV m152 proteins that appear to interact
transiently with MHC class I and II proteins (5, 53–55).
This transient interaction might alter the posttranslational
processing of MHC proteins, causing them to be mis-
sorted either to lysosomes or into other cellular compart-
ments, but not allowing transport to the cell surface. Addi-
tional studies are required to define more precisely the
molecular mechanisms by which UL16 affects intracellular
trafficking of NKG2D ligands.
Although UL16 is able to target ULBP1, ULBP2, and
MICB, it is noteworthy that it does not affect the closely
related MICA and ULBP3 molecules. MICA has been
shown to be induced by HCMV infection in vitro and
stimulate T cell–mediated recognition of the infected cells
(27), so one could speculate that another, as yet unidenti-
Figure 9. Cell surface expression of ULBP1,
ULBP2, or MICB correlates with sensitivity to NK ly-
sis. EL4 cells were transduced with amphotropic retro-
viruses encoding ULBP1 (A), ULBP2 (B), ULBP3 (C),
or MICB (D). The ULBP- or MICB-expressing EL4
populations were further transduced with VSVG-
pseudotyped retroviruses encoding both UL16 and
GFP. Transduced cells were separated into two cell
populations: those expressing GFP and UL16
(UL16 ) and those not expressing GFP and UL16
(UL16 ). Cell populations were used as targets in cyto-
toxicity assays using mouse NK cells (A–C) or human
NK cells (D). The results shown are representative of
three separate experiments.T
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fied, HCMV protein might target these other NKG2D
ligands under certain circumstances. Alternatively, the ab-
sence of HCMV-encoded antagonists for MICA and
ULBP3 might reflect an advantage to the host in the evolu-
tionary arms race with the virus. Similarly, m152 was re-
cently shown to down-regulate the mouse NKG2D ligand,
H60, but not the other mouse NKG2D ligands (56). It is
not clear whether the extensive polymorphism in the
NKG2D ligands, coupled with sequence variation between
strains of CMV, might alter the spectrum of NKG2D
ligands affected by UL16 or m152.
How might the interaction of UL16 and NKG2D
ligands play out in a virus infection in vivo? HCMV repli-
cates slowly compared with many viruses and does not
cause rapid cell destruction. Strong and long-lasting host
immune responses are generated to CMV antigens during
lifelong persistent infections that frequently involve many
cycles of latency and reactivation. Many studies have de-
scribed the inhibition of MHC class I and II antigen pre-
sentation by the HCMV US2, US3, US6, and US11 pro-
teins, and have suggested that this contributes to viral
persistence. The discovery that NKG2D ligands are up-
regulated by cells undergoing infection, stress, or transfor-
mation, and that their recognition by NKG2D receptor-
expressing cells can mediate destruction of these targets in
the absence of any changes in classical MHC-mediated an-
tigen presentation, provides a new paradigm for immuno-
surveillance. In this model, the pathogen is recognized in-
directly by immune effector cells, via changes in cellular
phenotype rather than by direct recognition of its encoded
antigens. The data presented here suggest that once again
the virus is “one step ahead of the game” (57), and that
HCMV expresses UL16 in order to prevent cell surface ex-
pression of NKG2D ligands and their recognition by
NKG2D-expressing immune effector cells. Strategies that
enable the virus-infected cell to avoid immune recognition
would be especially useful during the reactivation from la-
tency in the face of a primed and robust cellular immune
response. The need to evade preexisting humoral immu-
nity might also explain why UL16 and other HCMV-
encoded immunomodulatory glycoproteins are retained and
act intracellularly. However, it is also possible that UL16
might act during the primary stages of HCMV infection,
before the onset of an adaptive immune response, to inhibit
recognition by innate immune effector cells and “buy
time” for the virus to achieve a latent state.
In studying HCMV immune evasion mechanisms, there
are difficulties in extrapolating in vitro molecular and cellu-
lar experimental findings to in vivo relevance. HCMV is
highly species specific and therefore no in vivo model sys-
tems are available. The cell types, viral strains, and infection
protocols commonly used to study HCMV in vitro do not
always replicate the natural history of HCMV infection in
vivo. These difficulties prevent a precise definition of the
relative importance of proposed HCMV-encoded immune
evasion proteins, how they may work in concert with each
other, or even the types of infected cells in which they per-
form in vivo. Nevertheless, MCMV provides an experi-
mental model in which sophisticated manipulation of the
viral genome is now possible so that the roles of proposed
immunomodulatory proteins can be tested in the context
of an in vivo infection (58). Such studies have demon-
strated the in vivo relevance of MCMV proteins that
down-regulate surface expression of classical MHC class I
antigens and NKG2D ligands (56, 59), so there is a solid ra-
tionale to believe that UL16-mediated intracellular reten-
tion of NKG2D ligands is an important component of the
immune evasion arsenal of HCMV.
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